F598 / Alopexx - LARVOL DELTA

Insights into biofilm architecture and maturation enable improved clinical strategies for exopolysaccharide-targeting therapeutics. (PubMed, Cell Chem Biol) - "Remarkably, TG10 and F598 synergistically increased in vitro and in vivo activity, providing 90% survival in a lethal Staphylococcus aureus challenge murine model. Our advanced model deepens the conceptual understanding of PIA architecture and maturation and reveals improved design strategies for PIA-targeting therapeutics, vaccines, and diagnostic agents."

Journal • Infectious Disease

Poly-β-(1→6)-N-acetyl-D-glucosamine mediates surface attachment, biofilm formation, and biocide resistance in Cutibacterium acnes. (PubMed, Front Microbiol) - "PNAG was detected on the surface of C. acnes cells by fluorescence confocal microscopy using the antigen-specific human IgG1 monoclonal antibody F598...Dispersin B inhibited attachment of C. acnes cells to polystyrene rods, inhibited biofilm formation by C. acnes in glass and polypropylene tubes, and sensitized C. acnes biofilms to killing by benzoyl peroxide and tetracycline...acnes produces PNAG, and PNAG contributes to C. acnes biofilm formation and biocide resistance in vitro. PNAG may play a role in C. acnes skin colonization, biocide resistance, and virulence in vivo."

Journal • Acne Vulgaris • Dermatology • Infectious Disease

Alopexx Announces Presentation at IDWeek 2023 (PRNewswire) - "Alopexx, Inc...today announced that Colette Cywes-Bentley, Ph.D., Assistant Professor of Medicine at Brigham and Women's Hospital, is scheduled to present pre-clinical data at IDWeek 2023's Microbial Pathogenesis of Alzheimer's Disease symposium being held October 11-15, 2023 in Boston, MA....The presentation will discuss the results evaluating the role of targeting PNAG utilizing Alopexx's vaccine, AV0328 and monoclonal antibody F598....In murine models of Alzheimer's Disease, vaccination with Alopexx's AV0328 vaccine is able to prevent cognitive decline. AV0328 vaccination at 5 weeks or 5 months of age in APP-PS1 AD mice showed substantial protection against cognitive deficits and accumulation of beta-amyloid plaques at 12 and 15 months respectively."

Preclinical • Alzheimer's Disease • CNS Disorders